Skip to content
MARKETS / BALCAO / POSC
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Positron Corp. POSC

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$461,452
▼ 21.5% YoY
$-10.6M
In brief

What this company does

Positron is a medical technology company that co-develops, manufactures and sells PET and PET-CT imaging systems, delivering high-performance, cost-effective molecular imaging solutions that empower healthcare providers to improve the diagnosis and treatment of cardiovascular disease and other critical conditions. Positron Corporation is a medical technology company focused on advancing positron emission tomography (“PET”) imaging through the development, manufacture, and commercialization of PET and PET-computed tomography (“PET-CT”) imaging systems. The Company maintains a primary focus on cardiac PET imaging, which is widely utilized in nuclear cardiology for the diagnosis and management of cardiovascular disease. The Company’s PET and PET-CT imaging systems are co-manufactured through its partner, Neusoft Medical Systems, at its development and manufacturing facilities in Shenyang, China, including through affiliated entities. As of the date of this filing, the Company employed 10 full-time employees. Positron’s Headquarters is in North Tonawanda, NY.

Written from the business description in Positron Corporation's annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 461,452.00
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.5 · Net income -10.6
2.5M5.0M-4.0M-8.0M2010201120122013201420242025
Compound annual growth
−14.2%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−2298 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -2275.1% · Net -2297.8%
-1000%-2000%2010201120122013201420242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Gross margin-458.2%
Operating margin-2275.1%
Net margin-2297.8%
Return on assets-365.6%
EBITDAUSD -10.5M

Each USD of equity lost 2694 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2014 · FCF -2.4
-2M-4M2010201120122013201420242025

Total assetsUSD 4.0M
EquityUSD 1.4M
Gross debtUSD 153,686.00
DepositsUSD 375,000.00
Current ratio1.39×

Equity funds 36% of total assets.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420142013201220112010
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0·····
Income tax $B··0.00.00.00.0·
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B··−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.34−0.090.000.00−0.01−0.01−0.02
Dividend / sh $·······
Payout %·······
ROE %−2694.3······
Shares out B0.030.035.551.451.450.790.78

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 32 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 63 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onOTC market
Incorporated inTexas
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image